Measles Vaccine, Monovalent

What it is and how it works

Contains a live attenuated measles virus strain that replicates to a limited extent after injection and induces humoral and cellular immunity similar to natural infection, providing long-lasting protection against measles.

Indications

Active immunisation against measles, including early infant vaccination (e.g. from 6–9 months) in high-incidence or outbreak settings, and post-exposure prophylaxis within 72 hours of contact.

Dosage and administration (summary)

0.5 mL of the reconstituted vaccine by subcutaneous (or intramuscular) injection, according to the national immunisation schedule; further doses (usually as MMR or MR) are required.

Contraindications

Pregnancy; severe primary or acquired immunodeficiency or high-dose immunosuppressive therapy; anaphylaxis to a previous dose or to components such as neomycin; acute severe febrile illness.

Warnings and precautions

Pregnancy should be avoided for 1 month after vaccination. Administration should be delayed after receipt of immunoglobulin or blood products; tuberculin testing may be temporarily suppressed. Fever and rash may occur 5–12 days after vaccination, with a small risk of febrile seizures.

Pregnancy

Contraindicated in pregnancy.

Storage and supply

Store at 2–8 °C, protected from light; use promptly after reconstitution according to the product information.

Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.